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Backgrounds: Evaluating the efficacy of the loading and tapering dose of Phenobarbital versus oral Morphine in
the management of NAS.
Methods: This randomized, open-label, controlled trial was conducted on 60 neonates born to illicit drugs
dependent mothers at Vali-Asr and Akbar-Abadi hospitals, Tehran, Iran, who exhibited NAS requiring medical
therapy. The neonates were randomized to receive either: Oral Morphine Sulfate or a loading dose of
Phenobarbital followed by a tapering dose. The duration of treatment required for NAS resolution, the total
hospital stay and the requirement for additional second line treatment were compared between the
treatment groups.
Results: The Mean ± Standard Deviation for the duration of treatment required for the resolution of NAS was
8.5 ± 5 days in the Morphine group and 8.5 ± 4 days in the Phenobarbital group (P = 0.9). The duration of total hospital
stay was 12.6 ± 5.6 days in the Morphine group and 12.5 ± 5.3 days in the Phenobarbital group (P = 0.7). 3.3 % in the
Morphine group versus 6.6 % in the Phenobarbital group required adjunctive treatment (P = 0.5).
Conclusions: There were no significant differences in the duration of treatment, duration of hospital stay, and the
requirement for adjunctive treatment, between the neonates with NAS who received Morphine Sulfate and neonates
who received a loading and tapering dose of Phenobarbital.
Trial registration: This study is registered at the Iranian Registry of Clinical Trials (www.irct.ir) which is a Primary
Registry in the WHO Registry Network. (Registration Number = IRCT201406239568N8)
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Neonatal Abstinence Syndrome (NAS) is a set of signs
and symptoms that can occur in the neonates due to
intrauterine exposure to the opioids consumed by
mothers. NAS is characterized by gastrointestinal, central
nervous system, autonomic and respiratory signs and
symptoms [1]. Although the syndrome mostly occurs in
the context of antepartum opioid use, with the growing
prevalence of illicit drug use, other drugs have also been
described to cause NAS [2–7].* Correspondence: hoseindalili@yahoo.com
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unless otherwise stated.Based on a recent National Survey on Drug Use and
Health (NSDUH) in the United States 5.9 % of pregnant
women reported using illicit drugs during gestation [8].
Among the neonates who were exposed to illicit drugs
in utero, withdrawal signs and symptoms requiring med-
ical intervention develop in 27–91 % [4]. The treatment
rate is usually higher among poly substance and opioid
exposed neonates (60–70 %) and lower in stimulants
only exposed neonates (less than 10 %) whose the majority
do not require pharmacologic treatment [4–7, 9].
In the last decade with the increase in the incidence
of NAS, the total hospital charges have dramatically in-
creased [2].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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because of its serious and potentially life threatening
complications [10]. Although non-pharmacologic treat-
ments have been proposed for the management of NAS,
especially for the neonates born to cocaine or metham-
phetamines only dependent mothers [5], most neonates
with NAS require pharmacologic treatment [4, 11]. Many
agents have been proposed for the treatment of NAS in-
cluding opioids, anticonvulsants, α2-adrenergic antago-
nists, benzodiazepines, chloral hydrate and chlorpromazine
[11]. However the optimal pharmacologic treatment of
NAS has not been established and is still debated [3, 11].
In addition despite all the proposed treatments the dur-
ation of hospital stay for NAS remained relatively un-
changed during the past decade [2].
Morphine is the most commonly used drug as an initial
therapy for the treatment of NAS, however the evidence
suggesting the effect of prolonged opioid exposure on the
developing neonatal brain made the researchers search for
an alternative drug for initial NAS treatment [12].
Phenobarbital is another drug widely used for the treat-
ment of non-opioid NAS [4, 13]. some studies tried to
compare Phenobarbital versus Morphine in the treat-
ment of NAS; In the studies of Jackson et al. and Ebner
et al. shorter treatment duration was noted in the Mor-
phine treated group compared to the Phenobarbital
treated group [14, 15].
In the study of Jackson et al. all the mothers had re-
ceived Methadone during pregnancy. Also in the study
of Ebner et al. the mothers were only opioid dependent.
Considering the increasing prevalence of polysubstance
use during pregnancy [16], and that Phenobarbital is
preferred in the NAS due to intrauterine polysubstance
exposure [4, 13], studies are needed to compare Pheno-
barbital versus Morphine treatment in the neonates born
to mothers who used other addictive drugs in addition
to opioids during gestation. Additionally it is docu-
mented that the use of loading dose of Phenobarbital
significantly reduces the time for symptom control in
neonates with NAS [17]. In the available studies no load-
ing dose was used, therefore it is still unknown if there
is any differences in the duration of treatment and hos-
pital stay in the Morphine versus Phenobarbital treated
groups when loading dose of Phenobarbital is used [18].
We conducted this study to compare the efficacy of
initial Phenobarbital treatment with loading and main-
tenance dose versus Morphine treatment in the neonates
born to drug (opioids, stimulants and polysubstance)
dependent mothers who exhibit NAS requiring pharma-
cologic treatment. The primary goal of the study was to
evaluate the duration of treatment required for NAS
resolution. The total hospital stay and the requirement
for additional second line treatment were secondary
aims of the study.Methods
Study population and study design
This multicentric prospective, randomized, open label,
trial was conducted on 60 neonates who were born to
illicit drugs dependent mothers and exhibited NAS re-
quiring medical therapy who were admitted at Vali-Asr
and Akbar-Abadi teaching hospitals of the Tehran Univer-
sity of Medical Sciences, Tehran, Iran, from August 2009
through February 2014. Inclusion criteria were: neonates
born at ≥ 35 weeks of gestation, exposure to addictive
drugs in utero (determined by maternal history and con-
firmed by positive maternal urine toxicology screens dur-
ing the last trimester of pregnancy), demonstration of
signs and symptoms of NAS requiring treatment (three
consecutive Finnegan score of eight or more or two con-
secutive Finnegan score of 12 or more as calculated every
4 h by the physician). Exclusion criteria were: neonates
born at < 35 weeks of gestation, neonates who had intra
uterine growth retardation (IUGR), neonates with congenital
anomalies, neonates with major concomitant medical illness
requiring oxygen therapy, intravenous fluids or medications,
neonates with neurologic abnormality, breastfed neonates,
concomitant maternal Benzodiazepine or alcohol use, ne-
onates whose parents refused to give informed consent.
After explaining the whole procedure an informed
written consent was obtained from the parents, the neo-
nates then were randomly allocated in two groups: the
oral Morphine Sulfate treated group and the Phenobar-
bital treated group (Fig. 1).
A computerized random number generator was used for
sequence generation which was carried out by M.S. Simple
randomization with a 1:1 allocation ratio was used in this
study. We used the consecutive opaque envelopes for the
allocation concealment which was performed by F.N. The
envelopes were opaque when held to the light, and opened
sequentially and only after the participant’s name and other
details were written on the appropriate envelope. The im-
plementation of assignments was carried out by H.D.
The primary outcome of our study was the duration of
pharmacologic treatment needed for the resolution of
symptoms of NAS. Secondary outcomes were the total
duration of hospital stay, and also the requirement of
adjunctive therapy in each group.
This study was approved by the Research Deputy and
the Ethics Committee of the Tehran University of Medical
Sciences. (Reference ID = 88-03-30-9106).
This study is registered at the Iranian Registry of
Clinical Trials (www.irct.ir) which is a Primary Registry
in the WHO Registry Network. (Registration Number:
IRCT201406239568N8)
The protocol
In the randomly assigned oral morphine treatment group,
initially 1 ml of a 10 mg Morphine Sulfate vial was diluted
Fig. 1 Flow Chart of the study showing patients randomization
Table 1 The protocol of treatment with oral morphine sulfate
Finnegan
score
Volume of 0.4 mg/ml diluted
morphine sulfate
Dosage of
morphine sulfate
(ml/kg/24 h) (mg/kg/24 h)
8-10 0.6 0.24
11-13 1.2 0.48
14-16 1.6 0.64
17 and
above
2 0.8
Continued until Finnegan score remained below 8 for 72 h then ⇩ The
drug was weaned gradually by 10 % of maximal dose every day until it
was entirely discontinued
Cessation dose: less than 0.1 mg/kg/24 h
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of 0.4 mg/ml of Morphine, then depending on the Finnegan
score drug was administered in 6 divided doses/24 h as
follow: for a Finnegan score of 8–10: 0.24 mg/kg/24 h
(0.6 ml/kg/24 h), for a Finnegan score of 11–13: 0.48 mg/
kg/24 h (1.2 ml/kg/24 h), for a Finnegan score of 14–16:
0.64 mg/kg/24 h (1.6 ml/kg/24 h), and for a Finnegan
score of 17 and above: 0.8 mg/kg/24 h (2 ml/kg/24 h) of
Morphine Sulfate was administered. These doses of Mor-
phine Sulfate continued until Finnegan score remained
below 8 for 72 h then the drug was weaned gradually by
10 % of maximal dose every day until it was entirely
discontinued at the cessation dose of 0.1 mg/kg/24 h of
Morphine Sulfate (Table 1).
In the randomly assigned Phenobarbital treatment
group, initially a loading dose of 20 mg/kg IV or IM was
administered then if the symptoms persisted another
5 mg/kg was given every 8–12 h until the entire loading
dose would reach a maximum of 40 mg/kg. The main-
tenance dose was adjusted based on the loading doseand was initiated 12–24 h after the last loading dose as
follow: for a loading dose of 20 mg/kg the maintenance
dose was 5 mg/kg/24 h, for a loading dose of 30 mg/kg
the maintenance dose was 6 mg/kg/24 h, and for a
loading dose of 40 mg/kg the maintenance dose was
Nayeri et al. BMC Pediatrics  (2015) 15:57 Page 4 of 78 mg/kg/24 h administered IM or IV. These doses of
Phenobarbital continued until Finnegan score remained
below 8 for 72 h then the drug was weaned gradually by
10 % of maximal dose every day until it was entirely dis-
continued (Table 2).Statistical analysis
Sample size was calculated for a power of 80 %, α = 0.05,
β = 20 %, and a standard effect size of 0.84. All the statis-
tical analyses were performed using SPSS statistical soft-
ware (version 18.0.0: PASW, Chicago, IL). Data were
displayed using Mean, Standard Deviation (SD) and
Range. Mean comparisons between two groups were per-
formed using the t-test for independent samples. Further-
more The Chi-squared analysis, Fisher’s exact test,
independent-samples T test, One-Way ANOVA were used
to examine the relationship between maternal drugs and
demographic factors in two groups. The level of statistical
significance was set at P value < 0.05.Results
Descriptive statistics
This study evaluated 60 neonates with NAS who had
three consecutive Finnegan score of eight or more or
two consecutive Finnegan score of 12 or more as calcu-
lated every 4 h by the physician. 30 neonates were ran-
domly assigned to receive oral Morphine Sulfate and the
other 30 were randomly assigned to receive Phenobarbital.
In the Morphine treated group the mean ± standard de-
viation (SD) for maternal addiction duration was 4.4 ±
2.3 years; gestational age was 37.6 ± 1.4 weeks; birth
weight was 2774 ± 487 g; 5-min Apgar score was 9.5 ± 0.6;
Finnegan score before treatment was 11 ± 1.8; neonatal
age before treatment was 39.7 ± 2.5 h. 16 neonates were
female (53.3 %) while 14 neonates (46.7 %) were male.
In the Phenobarbital treated group the mean ± stand-
ard deviation (SD) for maternal addiction duration was
3.8 ± 3 years; gestational age was 37.6 ± 1.8 weeks; birth
weight was 2726 ± 490 g; 5-min Apgar score was 9 ± 1;
Finnegan score before treatment was 11.8 ± 2.2; neo-
natal age before treatment was 34.6 ± 2.5 h. 17Table 2 The protocol of treatment with phenobarbital
Initial loading dose of 20 mg/kg IV or IM ⇩ If the symptoms persisted
another 5 mg/kg was given q 8–12 h (the maximum loading
dose = 40 mg/kg)
Loading dose (mg/kg) Maintenance dose (mg/kg/24 h)
20 5
30 6
40 8
Continued until Finnegan score remained below 8 for 72 h then ⇩ The
drug was weaned gradually by 10 % of maximal dose every day until it
was entirely discontinuedneonates were female (56.7 %) while 13 neonates
(43.3 %) were male.
No significant differences were observed in the demo-
graphics between the two treatment groups (Morphine
versus Phenobarbital).
Drugs abused by mothers
The consumed drugs by mothers were Opium, Heroin,
Methadone, Cocaine, and Methamphetamine. No signifi-
cant differences in the maternal consumed drugs were
observed between the two treatment groups (Morphine
versus Phenobarbital) (Table 3).
Effect of treatment allocation on the study outcomes
The primary outcome of our study was to measure the
duration of pharmacologic treatment required for the
resolution of NAS symptoms. The mean ± SD for the
duration of therapy in the oral Morphine Sulfate group
was 206.3 ± 120 h (8.5 ± 5 days) with a range of 68–
504 h (2.8–21 days) while in the Phenobarbital group
was 204 ± 97 h (8.5 ± 4 days) with a range of 96–510 h
(4–21.2 days). There was no significant difference in the
duration of pharmacologic therapy required for NAS
resolution between Morphine Sulfate and Phenobarbital
treated groups (Table 4 and Fig. 2).
One of the secondary outcomes was the total duration
of hospital stay in each group; the mean ± SD for the
duration of total hospital stay in the oral Morphine
group was 304 ± 136 h (12.6 ± 5.6 days) while in the
Phenobarbital treated group was 300.5 ± 128 h (12.5 ±
5.3 days). There was no significant difference in the dur-
ation of total hospital stay between Morphine Sulfate
and Phenobarbital treated groups (Table 4).
Another secondary outcome was the requirement for
an adjunctive treatment to suppress NAS symptoms; one
neonate in the oral Morphine Sulfate group (3.3 %) and 2
neonates in the Phenobarbital treated group (6.6 %) did
not show good therapeutic response and needed an ad-
junctive therapy. In the Morphine Sulfate group Pheno-
barbital, and in the Phenobarbital group Morphine Sulfate
were used as adjunctive treatments. The need forTable 3 Drugs abused by mothers of the neonates randomized
to Morphine versus Phenobarbital treatment group
Drug Morphine group Phenobarbital group P value
N (%) N (%)
Opium 12 (40 %) 7 (23.3 %) 0.13 (N.S)
Heroin 2 (6.6 %) 1 (3.3 %) 0.55 (N.S)
Methadone 2 (6.7 %) 2 (6.7 %) 1 (N.S)
Cocaine 6 (20 %) 9 (30 %) 0.37 (N.S)
Methamphetamine 1 (3.3 %) 1 (3.3 %) 1 (N.S)
Polydruga 7 (23.3 %) 10 (33.3 %) 0.28 (N.S)
aA combination of the above drugs, N.S: Non Significant
Table 4 Comparison of the treatment duration, hospital stay and need to adjunctive therapy in the morphine sulfate versus
phenobarbital treated groups
Outcome Morphine sulfate group Phenobarbital group P value
Duration of treatment 8.5 ± 5 (days) 8.5 ± 4 (days) 0.9
(Mean ± SD) 206.3 ± 120 (hours) 204 ± 97 (hours) (N.S)
Duration of H.S 12.6 ± 5.6 (days) 12.5 ± 5.3 (days) 0.7
(Mean ± SD) 304 ± 136 (hours) 300.5 ± 128 (hours) (N.S)
Needing Adjunctive Tx 1 (3.3 %) 2 (6.6 %) 0.5
N (%) (N.S)
S.D: standard deviation, H.S: hospital stay, Tx: therapy, N.S: Non Significant
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difference between the two groups (Table 4).
Discussion
In this randomized clinical trial we evaluated 60 neonates
with NAS who were born to illicit drugs dependent
mothers, there were no significant differences in the dur-
ation of treatment required for the resolution of NAS,
duration of total hospital stay, and the requirement for ad-
junctive treatment, between the neonates randomized to
receive oral morphine sulfate and the neonates random-
ized to receive Phenobarbital. Currently the American
Academy of Pediatrics (AAP) recommends treating opioid
withdrawal with an opioid, while Phenobarbital is only
used as the adjunctive treatment for opioid withdrawal in
the United States. The results of this paper show that
using loading with titration doses of Phenobarbital can be
also a good and reasonable first line option especially forFig. 2 Kaplan-Meier curve showing the effect of Morphine (thin line) versu
required for the resolution of NASthe neonates with NAS who were exposed to polysub-
stance in utero, however more studies with larger sample
sizes are needed to confirm these results.
Morphine Sulfate is the most commonly used drug as
the first line treatment of both opioid and polydrug
withdrawal [18]. Many protocols for NAS treatment pre-
fer morphine because of its effectiveness, predictable
half-life and ease of administration [3]. However the
risks of prolonged and increased total cumulative expos-
ure to opioids require attention; the evidence suggest
that the opioids might negatively affect the growing
brain through a dose dependent way, these effects in-
clude the reduction of brain size, weight, proteins, RNA,
DNA, and neurotransmitters. These concerns made the
researchers search for alternatives to the opioids in the
management of NAS [12].
Phenobarbital is the second most commonly used drug
for the management of both opioid and polysubstances Phenobarbital (thick line) treatment on the duration of treatment
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polydrug withdrawal and also neonatal seizures due to
drug withdrawal [4, 5, 18]. Phenobarbital has been
shown to be superior to other sedatives in the manage-
ment of NAS [19]. and also it seems to have a particular
utility in neonates with polydrug exposure in utero [4, 13].
However, concerns about Phenobarbital use in the litera-
ture include impairment of suckling, and adverse effects
on the developing brain in long-term therapy [3].
Phenobarbital have been used in different protocols
for the treatment of NAS; titration dose alone, loading
dose with titration, short course and long course of treat-
ment [19]. in the study of Finnegan et al. the time required
to control NAS symptoms was significantly lower when a
loading dose of Phenobarbital was used [20]. In another
study Kahn et al. compared the short and long courses of
Phenobarbital treatment, they reported that there were no
significant differences in treatment failure and the require-
ment for adjunctive therapy in short versus long courses
of Phenobarbital treatment [21].
In the current study no significant differences were
observed in the efficacy of Morphine Sulfate versus
Phenobarbital in the treatment of NAS. This is in con-
trast to the previous studies; Jackson et al. and Ebner
et al. both reported that Morphine sulfate was superior
to Phenobarbital in the management of NAS due to
shorter duration of therapy [14, 15]. several factors could
explain the differences observed in the results compared
to the previous studies: 1. In the study of Jackson et al.
and Ebner et al. due to blinding no loading dose of
Phenobarbital was used, this could have introduced bias
in the favor of Morphine Sulfate. 2. The types of drugs
used by mothers; all the mothers in the study of Jackson
et al. and Ebner et al. had received opioids in their preg-
nancy, while in our study not all the neonates were ex-
posed to opioids in utero, and also in Jackson’s study
22 % in the Morphine group and 44 % in the Phenobar-
bital group had used Benzodiazepines while mothers
who had used Benzodiazepines were excluded from
our study. 3. The scoring system and inclusion criteria:
in Jackson’s study Lipsitz scoring system was used to
evaluate NAS severity and treatment, in Ebner’s study
Finnegan scoring system was used and the neonates
with Finnegan score of 10 or more were included in
the study, while we used Finnegan scoring system in
this study and the neonates with Finnegan score of
eight or more were included in the study. In addition
in our study breastfed neonates were excluded due to
the possible effect of breastfeeding on NAS symptoms
while in the previous studies these neonates were not
excluded.
The main strength of our study was using the loading
and maintenance dose of Phenobarbital and comparing
it to the effect of Morphine Sulfate on NAS treatment.Using short course of Phenobarbital treatment, involving
mothers with substance abuse other than opioids and
polysubstance users in the study were other strengths of
the study. There are several limitations in our study that
should be mentioned for future research: 1. we didn’t
measure the serum level of Phenobarbital in our study,
this could help in better and more practical interpretation
of the results. 2. measuring the adverse events of the treat-
ments was not among the purposes of the study, compar-
ing the adverse effects could help in better understanding
and decision making. 3. In this study women who used
nicotine were not excluded of the study, since nicotine
has been shown to affect the severity of NAS symptoms,
this point should be considered when interpreting the
results. 4. Due to the nature of the study, it was un-
blinded; this could potentially affect as the results of the
study. 5. To minimize the factors that could potentially
bias the results of the study, many exclusion criteria
were used, therefore the generalizabilty of the findings
should be considered when interpreting the results of
this study.
Conclusion
Phenobarbital and Morphine treatments are equally
effective in the management of NAS. Phenobarbital
treatment when used in a loading followed by mainten-
ance doses can be used as an effective and appropriate
initial treatment in the neonates with NAS who were
exposed to illicit drugs in utero (opioids, stimulants and
polysubstance) and exhibit severe withdrawal signs and
symptoms requiring pharmacologic intervention. There
were no significant differences in the duration of treat-
ment, duration of hospital stay, and the requirement for
adjunctive treatment, between the neonates with NAS
who received Morphine Sulfate and those who received
Phenobarbital.
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